News Category
TransCode Therapeutics has initiated a formal strategic review to evaluate options for maximizing value, including potential licensing, partnerships, ...
Creative Biolabs' tumor organoid co-culture models offer a more physiologically relevant 3D platform for evaluating CAR-T cell activity, addressing a ...
Creative Biolabs has introduced an integrated OMV and exosome-boosted CAR-T development platform to help researchers address poor infiltration, immuno...
TransCode Therapeutics reported positive Phase 1a safety results for TTX-MC138 at ESMO Congress 2026, with no dose-limiting toxicities and early signs...
Oncotelic Therapeutics published a peer-reviewed study showing its PDAOAI platform identified a four-gene prognostic signature in liver cancer, a step...
Coherence Neuro's $45 million Series A, backed by Peter Thiel and OpenAI, will fund a first chronic human trial of its SOMA implant for glioblastoma, ...
VERAXA Biotech is implementing New Approach Methodologies across its preclinical oncology programs, aiming to improve clinical translation and reduce ...
VERAXA Biotech is advancing its BiTAC platform to create antibody-based cancer therapies that activate only when two targets are present on the same t...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies across its preclinical programs, aiming to generate more human-relevant data and...
Dr. Mona Mofid's ninth San Diego Top Doctor award, alongside patient satisfaction honors and team recognition, underscores her two-decade leadership i...
A UK study finding that clearing immune fog can stop lung cancer before diagnosis underscores the promise of cancer interception, a field gaining prom...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies across its preclinical programs, potentially accelerating clinical advancement, ...
Lantern Pharma's Taiwan regulatory and IRB approvals for the Phase 2 HARMONIC trial of LP-300 enable expansion of a biomarker-driven study targeting E...
VERAXA Biotech (NASDAQ: VRXA) is implementing FDA-aligned New Approach Methodologies to reduce animal testing, accelerate clinical advancement, and cu...
Telomir Pharmaceuticals raised approximately $5.6 million in a PIPE financing that will fund clinical development of Telomir-Zn, including a Phase 1/2...
A new study reveals lymph-node-like structures in the skull's bone marrow that may serve as a local immune defense for the brain, potentially opening ...
Kairos Pharma's Phase 2 trial of ENV-105 in metastatic castration-resistant prostate cancer demonstrates a median PFS of 17.7 months versus 2 months f...
GeoVax's upcoming presentation at World Vaccine Congress Europe 2026 will detail its next-generation MVA-X vaccine and continuous cell-line manufactur...
The Hong Kong Convention and Exhibition Centre hosted 786 events in FY 2025–2026, including 25 new exhibitions and conferences, and has confirmed the ...
NHS England's new intraoperative brain tumor test, developed at the University of Nottingham, reduces genetic diagnosis time from eight weeks to two h...
A new blood-based method for identifying cancer-specific proteins could make personalized immunotherapy faster and more accessible for patients who ca...
The release of two billion pounds of cancer-linked chemicals into U.S. air in 2020 underscores the urgent need for both stronger prevention policies a...
Novogenia AG's H1 2026 report shows a 7% revenue decline but positive growth in DNA analysis and personalized health products, alongside strategic pro...
Scientists in South Korea have discovered a key protein that regulates brain cancer growth, potentially leading to new treatments for glioblastoma, th...
TransCode Therapeutics' updated Phase 1a data for TTX-MC138 demonstrate a 71.4% stable disease rate and a favorable safety profile, offering a potenti...
GeoVax's next-generation MVA-X vaccine demonstrated durable single-dose protection against lethal Clade I mpox in preclinical models, potentially simp...
Onco-Innovations is advancing its preclinical cancer candidate ONC010 toward first-in-human testing by integrating manufacturing, nanoparticle formula...
Patients with small cell lung cancer should ask about clinical trials at their first appointment, as timing can be crucial and emerging therapies offe...
Telomir Pharmaceuticals' Telomir-Zn inhibits osteosarcoma growth in human and canine cell lines, opening a potential dual veterinary-human development...
Dr. Wael Sakr has announced a one-time $1,000 scholarship for undergraduate pre-med students, aiming to ease financial burdens and encourage commitmen...
Creative Biolabs has broadened its single-cell and single-nucleus RNA sequencing and multi-omics offerings to help researchers overcome complex sample...
A comprehensive review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct functional subsets, offering a new ...
The September 17 Life Sciences Virtual Investor Forum will feature seven companies presenting live on novel treatments across oncology, fibrosis, drug...
VERAXA Biotech's appointment of Dr. Christoph Erkel as Chief Scientific Officer signals a strategic push to advance its conditionally active BiTAC® T-...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to proceed to a Phase 2 trial in multiple scler...
Onco-Innovations' CMO discusses the potential of ONC010, a novel PNKP inhibitor with dual selectivity mechanisms, as it advances toward first-in-human...
Quantum BioPharma's FDA clearance of its IND application for Lucid-MS marks a critical step toward a Phase 2 trial in multiple sclerosis, potentially ...
Kairos Pharma's CEO will present at the H.C. Wainwright conference, underscoring the company's progress in overcoming cancer drug resistance with its ...
GeoVax endorses the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to bolster diversified supply and preparedness.
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to enhance its financial leadership and support its oncology pipeline de...
Onco-Innovations advances its oncology pipeline with manufacturing and IND-enabling progress, strategic partnerships, and new funding, positioning ONC...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in Phase 2 trials marks a potential paradigm shift in MS tre...
OS Animal Health, a subsidiary of OS Therapies, is featured at the Moody Capital conference, highlighting its progress in developing OST-HER2 for cani...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, marks a potential paradigm shift in treat...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Pan African Clinical Trials Registry, marking a critical step in ...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a novel demyelination-targeting drug, could redefine MS therapy by addressing ...
As youth tobacco use hits historic lows, the FDA's authorization of modified risk claims for ZYN pouches underscores the need for a dual public health...
